TE_10822
Basic information Differential Expression Stage analysis Survival analysis Correlation analysis| TE family | MER45C |
|---|---|
| TE superfamily | Tip100 |
| TE class | DNA |
| Gene | LINC02267, - |
| Class | Chimeric, Intergenic |
| Coding | Non-coding |
| Tumor-specific score | 221.47 |
| Counts of samples | TCGA_tumor:392; TCGA_normal:1; GTEx:0 |
| TSS | chr4(+):96170310 |
Transcript isoforms
| Transcript_ID | Gene | Class | Coding | ORF | Position |
|---|---|---|---|---|---|
| teRNA_10822.1 | LINC02267 | Chimeric | Non-coding | Non-coding | chr4(+):96170311,96170666,96310703,96310794,96362860,96362880 |
| teRNA_10822.2 | LINC02267 | Chimeric | Non-coding | Non-coding | chr4(+):96170311,96170666,96310703,96310794,96451492,96451561,96581729,96581794,96818265,96818285 |
| teRNA_10822.3 | - | Intergenic | Non-coding | Non-coding | chr4(+):96170311,96170666,96172357,96172377 |
| teRNA_10822.4 | - | Intergenic | Non-coding | Non-coding | chr4(+):96170311,96170666,96172360,96172380 |
| teRNA_10822.5 | - | Intergenic | Non-coding | Non-coding | chr4(+):96170311,96170666,96252424,96252444 |
| teRNA_10822.6 | - | Intergenic | Non-coding | Non-coding | chr4(+):96170311,96170666,96262444,96262464 |
| teRNA_10822.7 | LINC02267 | Chimeric | Non-coding | Non-coding | chr4(+):96170311,96170593,96310703,96310794,96362860,96362880 |
| teRNA_10822.8 | LINC02267 | Chimeric | Non-coding | Non-coding | chr4(+):96170311,96170593,96310703,96310794,96451492,96451561,96581729,96581794,96818265,96818285 |
| teRNA_10822.9 | - | Intergenic | Non-coding | Non-coding | chr4(+):96170311,96170593,96172357,96172377 |
| teRNA_10822.10 | - | Intergenic | Non-coding | Non-coding | chr4(+):96170311,96170593,96173110,96173130 |
1
2
GTEx
The proportion of samples in which the TE-initiated transcript was expressed across 46 body sites in the Genotype-Tissue Expression (GTEx) project.
TCGA
The proportion of samples in which the TE-initiated transcript was expressed across 33 cancer types from The Cancer Genome Atlas (TCGA).
GTEx
The expression of TE-initiated transcript across 46 body sites from The Genotype-Tissue Expression (GTEx) project.
